{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T10:52:26Z","timestamp":1791543146519,"version":"4.3.4"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NordForsk Nordic Program on Health and Welfare"},{"name":"Nordic Pregnancy Drug Safety Studies"},{"name":"International Pregnancy Drug Safety Studies","award":["273366"],"award-info":[{"award-number":["273366"]}]},{"DOI":"10.13039\/501100005416","name":"Research Council of Norway","doi-asserted-by":"publisher","award":["262700"],"award-info":[{"award-number":["262700"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Topical retinoids are used to treat mild to moderate acne and should be avoided during pregnancy as a precaution given the teratogenic effect of systemic isotretinoin, despite limited safety data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To describe recent trends in the prevalence of topical retinoid use in women of reproductive age and to estimate risk of major congenital malformations (MCMs) associated with exposure of topical retinoids in early pregnancy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using publicly available nationwide data we estimated the annual prevalence of topical retinoid use in women of reproductive age (15\u201344\u2005years) 2006\u20132024 in Denmark, Iceland, Norway and Sweden. We subsequently used linked individual-level data to perform a population-based cohort study using nationwide registers to estimate prevalence of use during pregnancy and risk of MCM. We included all infants with a gestational age of at least 22 weeks in Denmark, Iceland, Norway and Sweden from 1996 to 2020. We compared risks of nongenetic MCM among infants with first-trimester exposure to topical retinoids with: (i) unexposed infants and (ii) infants with first-trimester exposure to topical azelaic acid or topical clindamycin. We estimated adjusted risk ratios (aRRs) with log-binomial regression, adjusting for country of birth, maternal age, and birth year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The prevalence of topical retinoid use among women of reproductive age in Denmark, Iceland, Norway and Sweden increased from 8.7 per 1000 in 2006 to 28.5 per 1000 in 2024. Of 3 869 586 infants included in the cohort, 0.86 per 1000 were exposed to topical retinoids in the first trimester. Among infants exposed to topical retinoids, 3.3% had any MCM (71 of 2172), compared with 3.0% among unexposed (111 404 of 3 671 023) [aRR 1.1, 95% confidence interval (CI) 0.87\u20131.38] and 2.6% among infants exposed to azelaic acid or clindamycin (295 of 11 139) (aRR 1.1, 95% CI 0.87\u20131.47).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We observed a 3.3-fold increase in topical retinoid use over the past 18\u2005years among women of reproductive age in the Nordic countries. We did not observe an increased risk of MCM associated with use of topical retinoids. Limiting to pregnancies resulting in a birth could underestimate both the prevalence of topical retinoid exposure and MCM risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljaf500","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T13:44:38Z","timestamp":1764942278000},"page":"640-647","source":"Crossref","is-referenced-by-count":1,"title":["Topical retinoid use in women of reproductive age and risk of major congenital malformations in exposed pregnancies: a Nordic cohort study"],"prefix":"10.1093","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9591-5152","authenticated-orcid":false,"given":"Erle","family":"Refsum","sequence":"first","affiliation":[{"name":"Department of Chronic Diseases, Norwegian Institute of Public Health , Oslo ,","place":["Norway"]},{"name":"Centre for Epidemic Interventions Research, Norwegian Institute of Public Health , Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Furu","sequence":"additional","affiliation":[{"name":"Department of Chronic Diseases, Norwegian Institute of Public Health , Oslo ,","place":["Norway"]},{"name":"Centre for Fertility and Health, Norwegian Institute of Public Health , Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5759-9366","authenticated-orcid":false,"given":"Carolyn E","family":"Cesta","sequence":"additional","affiliation":[{"name":"Centre for Pharmacoepidemiology, Department of Medicine, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6110-5891","authenticated-orcid":false,"given":"Mette","family":"N\u00f8rgaard","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Aarhus University Hospital , Aarhus ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Aarhus University , Aarhus ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Wittstr\u00f6m","sequence":"additional","affiliation":[{"name":"Centre for Pharmacoepidemiology, Department of Medicine, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helga","family":"Zoega","sequence":"additional","affiliation":[{"name":"Centre of Public Health Sciences, Faculty of Medicine, University of Iceland , Reykjavik ,","place":["Iceland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinna P","family":"Ulrichsen","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Aarhus University Hospital , Aarhus ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Aarhus University , Aarhus ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline M","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Chronic Diseases, Norwegian Institute of Public Health , Oslo ,","place":["Norway"]},{"name":"Centre for Fertility and Health, Norwegian Institute of Public Health , Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"issue":"Suppl. 1","key":"2026100906113436700_ljaf500-B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-3083.2011.04374.x","article-title":"European evidence-based (S3) guidelines for the treatment of acne","volume":"26","author":"Nast","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026100906113436700_ljaf500-B2","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1056\/NEJM198510033131401","article-title":"Retinoic acid embryopathy","volume":"313","author":"Lammer","year":"1985","journal-title":"N Engl J Med"},{"key":"2026100906113436700_ljaf500-B3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1177\/12034754211035091","article-title":"A clinician\u2019s guide to topical retinoids","volume":"26","author":"Motamedi","year":"2022","journal-title":"J Cutan Med Surg"},{"key":"2026100906113436700_ljaf500-B4","doi-asserted-by":"crossref","first-page":"392","DOI":"10.5114\/ada.2019.87443","article-title":"Retinoids: active molecules influencing skin structure formation in cosmetic and dermatological treatments","volume":"36","author":"Zasada","year":"2019","journal-title":"Postepy Dermatol Alergol"},{"key":"2026100906113436700_ljaf500-B5"},{"issue":"3 Pt 2","key":"2026100906113436700_ljaf500-B6","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/S0190-9622(97)70059-8","article-title":"The percutaneous absorption of topically applied tretinoin and its effect on endogenous concentrations of tretinoin and its metabolites after single doses or long-term use","volume":"36","author":"Latriano","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"2026100906113436700_ljaf500-B7","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/000155501750208119","article-title":"A double-blind investigation of the potential systemic absorption of isotretinoin, when combined with chemical sunscreens, following topical application to patients with widespread acne of the face and trunk","volume":"81","author":"Cunliffe","year":"2001","journal-title":"Acta Derm Venereol"},{"key":"2026100906113436700_ljaf500-B8","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0190-9622(91)70065-A","article-title":"The negligible systemic availability of retinoids with multiple and excessive topical application of isotretinoin 0.05% gel (Isotrex) in patients with acne vulgaris","volume":"24","author":"Jensen","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"2026100906113436700_ljaf500-B9","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/0140-6736(92)90854-V","article-title":"Ear malformation in baby born to mother using tretinoin cream","volume":"339","author":"Camera","year":"1992","journal-title":"Lancet"},{"key":"2026100906113436700_ljaf500-B10","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/0140-6736(93)90868-H","article-title":"Multiple congenital defects associated with maternal use of topical tretinoin","volume":"341","author":"Lipson","year":"1993","journal-title":"Lancet"},{"key":"2026100906113436700_ljaf500-B11","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0387-7604(00)00104-2","article-title":"Otocerebral anomalies associated with topical tretinoin use","volume":"22","author":"Selcen","year":"2000","journal-title":"Brain Dev"},{"key":"2026100906113436700_ljaf500-B12","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1345\/aph.17138","article-title":"Multiple congenital malformations associated with topical tretinoin","volume":"32","author":"Navarre-Belhassen","year":"1998","journal-title":"Ann Pharmacother"},{"key":"2026100906113436700_ljaf500-B13","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/0140-6736(93)91004-6","article-title":"First trimester topical tretinoin and congenital disorders","volume":"341","author":"Jick","year":"1993","journal-title":"Lancet"},{"key":"2026100906113436700_ljaf500-B14","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/S0140-6736(05)63790-7","article-title":"Safety of first-trimester exposure to topical tretinoin: prospective cohort study","volume":"350","author":"Shapiro","year":"1997","journal-title":"Lancet"},{"key":"2026100906113436700_ljaf500-B15","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/ajmg.a.30744","article-title":"Minor malformations characteristic of the retinoic acid embryopathy and other birth outcomes in children of women exposed to topical tretinoin during early pregnancy","volume":"136","author":"Loureiro","year":"2005","journal-title":"Am J Med Genet A"},{"key":"2026100906113436700_ljaf500-B16","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/bjd.14053","article-title":"Pregnancy outcomes following first-trimester exposure to topical retinoids: a systematic review and meta-analysis","volume":"173","author":"Kaplan","year":"2015","journal-title":"Br J Dermatol"},{"key":"2026100906113436700_ljaf500-B17","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1177\/0091270011429566","article-title":"Pregnancy outcome following exposure to topical retinoids: a multicenter prospective study","volume":"52","author":"Panchaud","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"2026100906113436700_ljaf500-B18","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/pds.4794","article-title":"Identifying pregnancies in insurance claims data: Methods and application to retinoid teratogenic surveillance","volume":"28","author":"MacDonald","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026100906113436700_ljaf500-B19","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/CLEP.S314959","article-title":"Nordic health registry-based research: a review of health care systems and key registries","volume":"13","author":"Laugesen","year":"2021","journal-title":"Clin Epidemiol"},{"key":"2026100906113436700_ljaf500-B20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.5324\/nje.v29i1-2.4053","article-title":"A common data model for harmonization in the Nordic Pregnancy Drug Safety Studies (NorPreSS)","volume":"29","author":"Cohen","year":"2021","journal-title":"Norsk Epidemiologi"},{"key":"2026100906113436700_ljaf500-B21","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1034\/j.1600-0412.2000.079006440.x","article-title":"Birthweight by \u00adgestational age in Norway","volume":"79","author":"Skj\u00e6rven","year":"2000","journal-title":"Acta Obstet Gynecol Scand"},{"key":"2026100906113436700_ljaf500-B22","volume-title":"Guidelines for ATC classification and DDD assignment, 2021","author":"WHO Collaborating Centre for Drug Statistics Methodology","year":"2020"},{"key":"2026100906113436700_ljaf500-B23","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","article-title":"Active-comparator design and new-user design in observational studies","volume":"11","author":"Yoshida","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"2026100906113436700_ljaf500-B24","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/1471-0528.17461","article-title":"Maternal age is highly associated with non-chromosomal congenital anomalies: analysis of a population-based case-control database","volume":"130","author":"Peth\u0151","year":"2023","journal-title":"BJOG"},{"key":"2026100906113436700_ljaf500-B25","author":"Higgins"},{"key":"2026100906113436700_ljaf500-B26","doi-asserted-by":"crossref","first-page":"e073141","DOI":"10.1136\/bmj-2022-073141","article-title":"Methods for deriving risk difference (absolute risk reduction) from a meta-analysis","volume":"381","author":"Murad","year":"2023","journal-title":"BMJ"},{"key":"2026100906113436700_ljaf500-B27","doi-asserted-by":"crossref","first-page":"i1981","DOI":"10.1136\/bmj.i1981","article-title":"Sparse data bias: a problem hiding in plain sight","volume":"352","author":"Greenland","year":"2016","journal-title":"BMJ"},{"key":"2026100906113436700_ljaf500-B28","doi-asserted-by":"crossref","first-page":"e0295897","DOI":"10.1371\/journal.pone.0295897","article-title":"Trends in harmful drug exposure during pregnancy in France between 2013 and 2019: a nationwide cohort study","volume":"19","author":"Louchet","year":"2024","journal-title":"PLOS ONE"},{"key":"2026100906113436700_ljaf500-B29","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00228-020-02868-2","article-title":"Prescription medicines with potential for foetal harm: dispensing before and during pregnancy in New Zealand, 2005\u20132015","volume":"76","author":"Donald","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"2026100906113436700_ljaf500-B30","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/1471-0528.13128","article-title":"Dispensing of potentially teratogenic drugs before conception and during pregnancy: a population-based study","volume":"122","author":"Zomerdijk","year":"2015","journal-title":"BJOG"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljaf500\/65823664\/ljaf500.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/194\/4\/640\/65823664\/ljaf500.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/194\/4\/640\/65823664\/ljaf500.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T10:11:41Z","timestamp":1791540701000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/194\/4\/640\/8375699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12,9]]},"published-print":{"date-parts":[[2026,3,19]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljaf500","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2025,12,9]]}}}